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Abstract  
Introduction: Research is being carried out to develop and test new potentially more effective tuberculosis vaccines. Among the vaccines being 
developed are those that target adolescents. This study explored the stakeholders’ perceptions about adolescent participation in a hypothetical 
tuberculosis vaccine trial in Ugandan adolescents. Methods: Focus group discussions with adolescents, parents of infants and adolescents, and 
key informant interviews with community leaders and traditional healers were conducted. Results: The majority of the respondents expressed 
potential willingness to allow their children participate in a tuberculosis vaccine trial. Main motivations for potential participation would be being 
able to learn about health-related issues. Hesitations included the notion that trial participation would distract the youths from their studies, fear of 
possible side effects of an investigational product, and potential for being sexually exploited by researchers. In addition, bad experiences from 
participation in previous research and doubts about the importance of research were mentioned. Suggested ways to motivate participation 
included: improved clarity on study purpose, risks, benefits and better scheduling of study procedures to minimize disruption to participants’ 
academic schedules. Conclusion: Findings from this study suggest that the community is open to potential participation of adolescents in a 
tuberculosis vaccine trial. However, there is a need to communicate more effectively with the community about the purpose of the trial and its 
effects, including safety data, in a low-literacy, readily understood format. This raises a challenge to researchers, who cannot know all the potential 
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Globally, one out of every three people is estimated to be infected 
with the causative agent Mycobacterium tuberculosis[1]. The World 
Health Organization (WHO) aims to eradicate tuberculosis (TB) as a 
public health problem by 2050 [2]. However, eradication will be 
impossible without an effective vaccine [1]. Currently the only 
licensed TB vaccine, Bacille Calmette-Guerin (BCG) is given early in 
life and results in variable and waning immunity to TB [3]. 
Therefore, research is being carried out to develop and test new 
potentially more effective TB vaccines that could substitute or 
complement BCG [4-8]. Among the vaccines being developed are 
those that target infants and also adolescents [1]. Adolescents are 
also considered a target group for TB vaccines due to the fact that 
the rate of TB infection increases steeply in adolescence [9]. Since 
the TB incidence is highest among developing countries, it is these 
countries that will benefit the most from the development of a new 
TB vaccine [10]. Therefore, for scientific, ethical and economic 
reasons, phase III TB vaccine trials, should ideally take place in 
communities where the incidence of infection and/or disease is high 
[10]. Many populations in developing countries like Uganda do meet 
the criteria. Thus, many volunteers living in high-burden areas are 
needed for phase II and III efficacy TB vaccine trials. This raises 
one important principle of research ethics, i.e. informed consent. 
Informed consent is a process (occurs at enrolment and throughout 
the study), not just a form signed for the legal protection of an 
institution [11]. It is based on complete revelation of the facts about 
the study. It is meant to inform potential participants about the 
purpose, risks, potential benefits, alternatives to research and their 
rights as study subjects. This is to allow people to make intelligent 
decisions whether or not to participate based on their own goals 
and values [12].  
  
While the above views are clear, the question is how eager are 
communities in high burden settings to allow their youth to 
participate in TB vaccine trials. What are their views regarding 
research in general and TB vaccine trials in particular? The 
preparedness of the local communities needs to be assessed. 
Therefore understanding willingness of parents to allow their 
children to participate in vaccine trials is critical. Very few studies 
have reported willingness to participate (WTP) in TB vaccine trials 
and the factors associated with this willingness [13, 14]. A study on 
WTP in TB vaccine trials among adolescents in South Africa, found 
that acceptability depended on the invasiveness of study procedures 
[13]. Among adults living with HIV, willingness to be vaccinated 
with a hypothetical effective and licensed TB vaccine was found to 
be high, at 84.5% and 92.6%, respectively [14]. The factors 
associated with willingness to be vaccinated included good TB 
knowledge and high perceived risk of contracting TB [14]. Majority 
of studies on WTP in vaccine trials concern HIV vaccines. In these 
studies the perceived benefits of the vaccine and altruism were the 
main factors associated with WTP in trials [15, 16]. In a study in 
Kenya on willingness of parents to have their children receive an 
infant HIV-1 vaccine, the majority (97%) were willing [17]. For 
those who were not willing, reasons for not wanting to enroll 
included concerns about side effects, partner objection, fear of 
discrimination, and HIV-1 acquisition [17]  
  
Therefore, understanding the parents /care takers and potential 
participants' willingness to take part in a trial is critical for planning 
potential TB vaccine trials. Uganda was one of the high TB burden 
countries which were identified as a potential venue to conduct new 
TB vaccine trials by EDCTP and Aeras. To our knowledge, no studies 
have examined parents/caretakers willingness to allow their 
adolescents participate in a TB vaccine trial in Uganda. Our study 
explored willingness of adolescents, parents and care takers in 





The study was carried out in June and July 2008 in the Iganga/ 
Mayuge Demographic Surveillance Site (DSS), located in eastern 
Uganda, about 120 km east of the capital Kampala. The DSS is 
predominantly rural (90% rural), but also partly semi-urban (Iganga 
Town). The main source of income in the area is subsistence 
farming (Iganga District). In 2008, the DSS population was 68,000 
individuals in 12,000 households. The DSS was established in 2005 
and the activities carried out include vital registration of births, 
deaths, pregnancies, and migration three times per year and have 
been described elsewhere [9]. In addition, this area has been well 
researched for special studies [18]. Therefore the community 
members were relatively familiar with health research. The DSS is 
found in the Busoga region, a traditional Bantu kingdom situated in 
south-eastern in present day 
Uganda. It is a cultural institution that promotes popular 
participation and unity among its people, through cultural and 
developmental programs for the improved livelihood. The Basoga, 
the people of Busoga, speak Lusoga and are the second largest 
ethnic group contributing about eight percent of the total population 
in Uganda [19]. The Busoga region is a patriarchal society and 
predominantly of the Islam religion. Main economic activity is 
farming and fishing [19]. HIV prevalence in this region is 5.5% [20].  
  
Study design  
  
This was an explorative qualitative study using focus group 
discussions (FGDs) and Key informant interviews (KIs) in June- July 
2008. The study was part of a larger study on capacity building to 
conduct phase III TB vaccine trials in the Iganga-Mayuge 
Demographic Surveillance Site (DSS), designed to estimate TB 
incidence among infants and adolescents. The current study's 
primary aim was to assess knowledge, attitudes and health seeking 
behavior towards TB in the communities [21] as well as community 
willingness to allow their children participate in a hypothetical TB 
vaccine trial. In this paper, we focus on the willingness to 
participate in TB vaccine trial aspects of the study.  
  
Data collection  
  
FGDs and KIs were conducted. In this particular study, FGDs were 
used because they are naturally designed to elicit normative views 
and perceptions [22]. FGDs were held separately with male and 
female parents/caretakers of infant and adolescents, adolescent 
boys and girls. Twenty four FGDs were conducted, including six 
FGDs of young mothers/fathers/caretakers (aged <36 years) of 
children, six of mothers/fathers/caretakers of adolescents, six of 
mature mothers/fathers/caretakers aged (>36 years), two of 
adolescent girls in school, two for adolescent boys in school and two 
for adolescents out of school (one for girls and one for boys. KIs 
were conducted to get detailed information about community's 
views [23] with regard to necessary conditions and constraints on 
allowing their children to participate in a TB vaccine trial. Key 
informants included two local council leaders (LCs), two religious 
leaders (a Muslim and a Christian), two elders, two sub-county TB 
supervisors (health assistants) and two traditional healers. The KI 
respondents were chosen purposefully because they play a 
significant role in society and are opinion leaders upon who young 
parents look for advice. In addition, they were recruited because 
they are in constant touch with the community and therefore widely 
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knowledgeable about community dynamics. FGDs and KIs were 
conducted at the village level. Individuals were identified with the 
help of the LCs. FGDS were grouped by such factors as age and sex, 
as homogeneity among focus group participants can facilitate 
sharing by eliminating status disparities. Study methodology has 
been described in detail elsewhere [21]. Topics for the interview 
guides, for both FGD and KI were designed to elicit participants' 
views about WTP in a TB vaccine trial for the adolescents and 
willingness to allow their children participate, for the parents and 
caretakers.  
  
Data management and analysis  
  
Data collection instruments for FGDs and KIs were pre-tested. 
Interviews with health workers were conducted in English, while the 
other interviews were conducted in the local language, Lusoga. 
Tape recordings and notes were used to record the interviews, 
which were later transcribed. All interviews were transcribed by 
moderators, and those in Lusoga were translated into English. 
Transcripts were read and re-read several times to get an overall 
picture. Analysis was carried out using content analysis method. 
Data were analyzed manually by coding related responses into 
themes [24]. These themes were shared among the authors for 
agreement.  
  
Ethical considerations  
  
The study was approved by the Makerere University School of Public 
Health Institutional Review Board and the Uganda National Council 
for Science and Technology. The interviews were conducted only 
after informed consent was obtained from the study participants. 
Participation was entirely voluntary and the respondents were 
informed that at any time during the FGD or KI they could decide to 
opt out with no negative consequences. The interviews were carried 





Both individual interviews and FGDs revealed similar views; 
therefore, the presentation of results from the two groups is 
integrated. Where necessary, notes are made about the similarities 
or differences between the two sources of data. The data are 
presented according to the themes that emerged and illustrative 
quotes from respondents are used to exemplify the results.  
  
Willingness towards TB vaccine trial  
  
Study participants expressed potential willingness to allow their 
children participate in a TB vaccine trial. Respondents' most 
mentioned reason for participation was to be able to access learning 
opportunities about health related issues in their communities. 
"When we get visitors like you (meaning researchers), we are able 
to get knowledge. We are able to learn how to remain healthy. So 
it's good to get involved." FGD young mothers. In one FGD for the 
elderly men, interest in participation in the hypothetical TB trial was 
altruistic, to help find a vaccine to protect their loved ones and the 
rest of the Ugandans. "Because you have love for the life of people 
of Uganda" FGD elderly men.  
  
Though participants understood that the TB vaccine trial would be 
an experimental vaccine and were willing to have their children 
participate, there was a concern about the safety and side effects of 
taking part in unlicensed vaccine. Some KIs and FGDs mentioned 
they would be willing to allow their children participate, if assured 
that the trial was safe. "Yes we will be willing, as long as it's not 
harmful." FGD mothers of adolescents  
  
Fears/concerns/inconveniences about new TB vaccine trial  
  
Risk perception of the proposed vaccine trial  
  
Respondents expressed their unwillingness to participate in a TB 
vaccine trial due the discomfort with the notion that they are "being 
experimented upon" and that the investigational product could be 
harmful. There was a feeling among some, that such activities like 
clinical trials (and even immunization with licensed vaccines) were 
deliberate strategies to control the population growth, particularly in 
Africa. A few FGDs and KIs also referred to an incident where 
children died following routine immunization. Community members 
wanted an assurance that the investigational vaccine would be safe 
for those who would receive it. Some preferred to await licensure. 
"You people are accepting but some time back they vaccinated our 
children and there was an allegation that the ones who were 
immunized will not give birth" FGD mothers of infants. "Some of the 
parents may not accept. Some may think that it's a way of 
preventing their children from giving birth... Others think they want 
to reduce your life span. Laughter!"  FGD adolescent girls. "Because 
of what happened (referring to the incident where children died 
following routine immunisation), I shall wait for others to take 
theirs, then I take mine." FGD mother infants. Elderly men were 
particularly suspicious of the placement of a trial in their community 
due to safety concerns about the vaccine. "It should be tried in an 
area that's highly populated such that in case of anything, there is 
no effect on our population. Or why don't you try it on yourself 
(meaning researchers) first?" FGD elderly fathers of infants. Two 
interviewees observed that if people really fully grasp the 
experimental nature of vaccine trials they will be scared and will not 
accept. "You know people are very difficult, if you tell them it's a 
trial, they will not accept unless if you tell them that it has been 
tried elsewhere." Traditional healer. "If you tell the people that it's a 
trial, they will have doubt and will be scared off." Head teacher  
  
Side effects of the vaccine  
  
Participants, even those who were willing to have their children 
participate, raised concerns mainly around potential safety issues. 
Most FGDs were concerned that the investigational product could 
have side effects on the study participants such as illness to their 
children, including TB or even death. "Also parents need assurance 
that what they (the researchers) are going to do is good and won't 
harm their children." FGD young mothers of infants. "The feared 
problem is that the adolescent may develop TB during the study and 
the parents will think that their child has got TB as a result of the 
new vaccine." FGD adolescent boys out of school  
  
Discomfort caused by the trial procedures  
  
Some of the FGDs and KIs were concerned about the potential 
discomfort associated with the study procedures such as injections 
in the event that a new vaccine candidate was to be administered 
by injections. "One of the difficulties is the children might fear to be 
injected and so fails to turn up. If they hate taking tabs when sick, 
what will happen if they are to be injected?" Women-Care takers 
adolescents  
  
Inconveniences due to follow up  
  
Following up of the participants was viewed as a good thing and 
would help the study team discover the side effects of the 
investigational product early. It was also interpreted as a sign that 
the study team cares about their study participants. Some viewed it 
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as a privilege to have health workers visit them in their homes 
rather than them going to the health facility. Having a health worker 
visit them at home was seen as an opportunity to get answers to 
their health-related questions, saving them the transport to go to 
health facilities. However, some FGDs and KIs raised concerns about 
the follow up process, mentioning that it could lead to stigmatization 
of the participants and their families. An FGD participant in the 
young mothers group believed that being followed up might make 
people think that they were HIV infected. While in another FGD said 
that participants will be stigmatized and assumed to have TB. 
"People would laugh at you thinking you have TB." FGD adolescent 
girls. "This participant will not feel free with his other friends. They 
will keep on teasing him and telling him/her that he/she will get side 
effects of the vaccine." FGD adolescent boys out of school  
  
Priority setting, who makes the decision and how?  
  
In most KIs and FGDs, community members including the youths 
were perceived as not to have time due to many commitments. 
Participating in the proposed trial and other research activities was 
not viewed as a priority. This was commonly mentioned by FGDs 
from fathers. "Some people could be willing but when they do not 
have time."Others say it's time wasting." FGD young fathers. It was 
also expressed that the study participants would lose valuable 
academic time due to the follow up process and this was commonly 
mentioned by the FGDs among adolescents. "If it's exam time this 
(follow up) can disorganize you." FGD adolescent boys. "The 
problem. I am sensing is if one is told to participate, say 3 times a 
week, it becomes time wasting. So one may decide to go and do 
his/her other duties since he/she will not be getting anything from 
the study." FGD adolescent boys out of school.  
  
Benefits to the participants  
  
The issue of how much youth benefit from participation in a vaccine 
trial and other research activities was raised.  
  
Research ethics: Motives and behaviour of researchers  
  
There was a perception that Ugandan and foreign researchers gain 
a lot out the research work compared to benefits accrued by the 
communities. This perception was common among men (KIs and 
FGDs), as exemplified by the following quotes from FGDs for men. 
"Some people think that researchers benefit a lot yet they do not 
share that money with the information providers." FGD elderly men. 
"People think it's the researchers who benefit. They come and ask 
you so many questions but you do not benefit in any way." FGD 
young fathers. It was also feared that the study team might try to 
take advantage of adolescents or family members, such as having 
sexual relationships with the study participants or their parents. 
"One might lose her marriage because the man might think you 
have an affair with the researchers." FGD young mothers of infants.  
  
Experience from previous research  
  
Negative experiences in prior research participation within the DSS 
shaped expectations of TB vaccine trials. For example; lack of 
feedback and insufficient attention to community norms regarding 
sensitive issues was given as a reason for lack of interest in 
participating in the hypothetical new TB vaccine trial. In addition, 
some respondents mentioned that they were tired of research. 
"Lack of feedback. Because many researchers come but they do not 
give us reports." FGD young men. "At times experience from 
previous researchers who were not good." FGD Young fathers. 
Having a good relationship with the study participants was raised as 
an important means of keeping participants interested. One FGD for 
young women, it was mentioned that people are already fatigued 
with research and so the researchers were advised to pay more 
attention to the relationship with the communities to make their 
study appealing and thus be able to keep participants engaged. 
"People are fed up of research, so you need to be very convincing." 
FGD mother of infants. "It all depends on your communication skills. 
If you talk to people well, then they will be encouraged to continue 
participating." FGD mothers of adolescents  
  
Illiteracy and lack of confidence  
  
Another reason given for reticence was due to lack of formal 
education and being uninformed about the potential importance of 
research. Lack of confidence was mainly attributed to lack of formal 
education and this was felt to bring about difficulty in interacting 
with the researchers on an equal footing. Some FGDs reported that 
some people who lacked formal education felt inhibited by the use 
of English and fear that they would not grasp what the research is 
about. "It depends on the level of understanding in the family. 
Some families are more enlightened and so want to learn more." 
FGD elderly men.  
  
Ways to motivate/encourage participation  
  
Informed Consent  
  
Though participants understood that this was a trial of an 
investigational product, sensitization to the parents and adolescents 
about the study objectives and the safety of the trial vaccine was 
deemed essential before they could make a decision. Most of the 
FGDs and KIs reported that the way to encourage them and their 
children participate in the study was by giving them comprehensive 
and readily understandable information about the investigational 
product. Participants felt that sensitizing the community about the 
purpose and procedures of the trial was critical on deciding whether 
to participate or not. Continuous sensitization and counselling about 
the importance of their participation was also reported to be 
necessary during the trial in order to encourage retention. 
Participants reported that even before deciding on whether to 
participate, they should be given information on how they will 
benefit from the trial. "Tell us the purpose of this new vaccine, its 
name and people will be willing depending on how they would have 
understood." FGD young men "In most cases people need to know 
the purpose of the study and how they will benefit before deciding 
to participate." FGD young men.  
  
Whom to involve in decision making  
  
In making a decision to participate in the proposed TB vaccine trial, 
all FGDs and KIs indicated that consulting their local leaders (LCs) 
was very important before deciding to participate in the 
investigational product trial. Information from LCs was reported to 
be the most trusted by the community members. Majority of the 
participants were of the view that researchers should go through 
their LCs when introducing the investigational product trial. In 
addition, the other important people to consult were their spouses, 
relatives, elders in the community and friends. Although there was 
concern about cooperation by village leadership expressed by at 
least one. "After my wife, I can also involve my neighbour" FGD 
elderly men. "Any one older than me, local leaders, health workers 
in the area and anyone who has ever participated in research" FGD 
participant young men. The gender and age hierarchies in the 
community were significant influences on decision making. Some 
women expressed that they did not have a decisive role in whether 
or not children would be allowed to participate. "For us who are 
married, our husbands are the ones who make decisions and they 
may refuse the children to join the study; saying it"s time wasting." 
FGD mother of infants  
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Incentives to the participants  
  
The majority of FGDs and KIs mentioned that the way to encourage 
participation was to give participants incentives as a way of 
motivating them and also compensating for their time spent in the 
trial. Suggestions varied from allowances, medical treatment and 
emotional solidarity in case of adverse events, mosquito nets, food, 
clothing and school fees. "You need to compensate for our time. 
You find that we leave our work behind to come and participate in 
such things but in most cases its you people (the researchers) who 
benefit." FGD mother of infants. "People expect immediate 
assistance in case they get in problems... Expectation to get some 
help in case you get problems, for example if you donate blood. 





This study explored willingness of parents and care takers in 
allowing adolescents participate in future TB vaccine trials. Findings 
from this study suggest that community members may be willing to 
allow their children participate in a hypothetical TB vaccine trial 
under certain conditions. The reasons given for the interest to 
participate were the opportunity to learn about health related 
issues, to receive tangible benefits, and help their community. The 
decision to participate in research would hinge on the quality of 
information provided about the study, its purpose, risks and how 
they benefit (i.e. informed consent). Youth participation in research 
was not considered a priority by some, and was felt to detract them 
from academic and economic activities. Similarly, participants felt 
that to be encouraged to participate; they should be compensated 
for their time they would spend in the trial or be given incentives, 
since researchers also get paid. Bad experiences in previous 
research and the fatigue from research participation were reported 
as negative influences upon future trials. There was fear that the 
investigational product could have bad side effects and so an 
assurance that the investigational product is safe was critical before 
participation. The issue of assuring potential participants that a trial 
product is safe and without risks, is at odds with the clinical 
uncertainty that is at the heart of phase III clinical trials. This 
precondition represents a dilemma for trialists since a full safety 
profile is never available at the time of an efficacy trial. In vaccine 
development the side effects of the trial product are not fully known 
and so the researchers cannot disclose all the potential side effects 
of the trial product [11]. This calls for both an ethical guidance as 
well as a personal determination whether the balance between 
potential benefit and potential harm is a positive one. Researchers 
in vaccine trials have to be as honest as possible. Though this might 
inhibit participation, the researchers have to give the right 
information to ensure that the potential participants understand the 
nature of the study and why they are being asked to participate, 
with emphasis that risks are not yet known and also the benefits to 
the study participants. This process has to continue throughout the 
study [25]. The importance of providing information about the 
research to assist in decision making process to participate in 
research has been reported by Mahomed in S. Africa [13].  
  
In addition, previously it was thought that populations in Africa may 
not grasp the many layers of informed consent [25]. The findings in 
this study show this is false. Respondents were demanding to be 
given details of the trial, i.e. its purpose, risks and the benefits 
involved before they could make a decision to participate. They 
went on to emphasise that to encourage continuous 
participation/retention in the study, this information about the study 
has to be continuously given, which is in line with the principle of 
informed consent [26]. Youth's fear of being teased because of 
participation in a TB vaccine trial was raised. This hesitation was 
similar to what was reported in a study by Sahay et al in India [27]. 
The issue of how participants personally benefit from the study was 
also mentioned. The benefits tended to be more of individual 
(materialistic) than to a broader society (altruism) [27, 28]. The 
community's motivation to participate in research including being 
treated well, receiving medical treatment , opportunity to learn, and 
incentives like food and allowances has been found in other studies 
[27-32]. However, it has been argued that some of these incentives, 
like improved medical care provided during the trial may constitute 
an undue inducement and hence be considered coercive [33]. 
Therefore, compensation of the trial participants should be fair, not 
to induce participation [33]. Respondents suggested that the 
researchers should test the investigational product on themselves 
first is similar to what was found elsewhere [27, 30] where some 
felt that they were singled out to be used as "guinea pigs" and 
being exploited because of their race [27, 30, 31]. This reveals the 
level of mistrust of researchers' motives and rationales [31]. 
Decision making process was reported to involve consulting the local 
leaders, spouses, elders and relatives. This is similar to what had 
been reported elsewhere in Africa [25]. Previous studies in various 
African countries show that for better or for worse, community 
leaders are the gatekeepers of their communities [25, 34]. This 
underscores the significance of researchers going through the 
community leaders before seeking consent from the study 
participants, though this does not replace the consent from 
individuals. This study brings out the importance of continuous 
sensitization to the study participants before enrolment and 
throughout the study period as one of the factors to enhance 
participation. Provision of study information is related to trust [27, 
31] and that continuous information and communication during the 
study is more effective in facilitating enrolment and retention than 
the information provided during the consent process alone [31]. 
This is in line with the principle of informed consent [26]. 
Participants need to be aware of the autonomy to leave the trial at 
any time. Like most qualitative study results, the findings of this 
study cannot be generalized beyond the context we studied. It 
explores WTP in a hypothetical TB vaccine trial among adolescents 
and of their parents/caretakers and therefore may not reflect the 
actual WTP and consent when a specific, concrete set of risks and 
benefits are presented. However, use of these qualitative methods 
facilitated richer understanding of the barriers and facilitators in 
allowing adolescents participate in a TB vaccine trial. In addition, 
this study had a wide community representation i.e. views from 
caretakers/parents, adolescents and opinion leaders. This 
representation may have given rich and representative views of the 





The findings from this study provide a valuable insight on the 
barriers of implementing vaccine trials in developing countries. 
Informed consent and how participants benefit were stressed as 
important things to be considered in planning for these trials. 
Researcher's behaviour and trustworthiness was also considered 
critical. Since this was a hypothetical study on WTP to participate in 
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